No annual revenue total was found in Dermata Therapeutics, Inc.'s SEC filings.
Dermata Therapeutics, Inc. (DRMA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-8.37M
+19.0% vs year-ago TTM
Operating cash flow (TTM)
$-8.08M
+26.3% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-3.36
Dividend per share
None
Shares outstanding
4.02M
-25.9% vs prior year
Net cash
$10.80M
FY 2021
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M |
| Diluted EPS | -$8.16 | -$80.32 | — | — | — |
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922,634 | $1.5M |
| Stockholders' equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M |
| Cash and investments | $7.5M | — | — | $6.2M | $10.8M |
| Total debt | — | — | — | — | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 17, 2026 | Aug 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 27, 2026 |
All 371 Dermata Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.